The curious case of

Perhaps you've heard of Xoma ($XOMA), a biotech at work on a do-it-all anti-inflammatory antibody now undergoing three Phase III trials. The company took a beating on Wall Street last year when the treatment, gevokizumab, failed a Phase II osteoarthritis study, spurring doubts about its prospects in another 10 or so indications and leading investors to wonder whether the antibody actually works. But if you went to Xoma's website on Thursday, you got a cheery affirmation of gevokizumab's potential. The images, marketing copy, stock charts and stock photos that once adorned were replaced with a single statement in unstylized text: "It works!" Whether that was an unrelated hosting glitch, an internal joke gone awry or, as some suggested on Twitter, a tongue-in-cheek hack job, is up in the air. Xoma didn't respond to email inquiries on the issue, and the site has since returned to its normal layout.

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.